To examine the environmental impact of inhaler formulations used for asthma and COPD and the barriers to adopting lower-emission alternatives.
Approach:
Emission Comparison: Inhalers for asthma and COPD in the US generate emissions comparable to 530,000 cars annually.
Insurance Coverage Analysis: Studies assessed the coverage of inhalers by insurance plans, highlighting the limited availability of dry powder alternatives.
Cost Analysis: Investigated the out-of-pocket costs associated with different inhaler types and their impact on patient access.
Key Findings:
SABAs, ICSs, and ICS-LABAs together represent 98% of inhaler-associated emissions.
Only 33% of insurance plans cover dry powder SABAs, limiting patient access.
Metered-dose inhalers are generally cheaper than dry powder alternatives, influencing formulary coverage.
Interpretation:
Market competition and pricing structures significantly affect the availability and use of lower-emission inhalers.
Limitations:
Existing insurance and payment structures may hinder the adoption of environmentally friendly inhalers.
Potential increases in costs for insurers and patients if dry powder inhalers are mandated for coverage.
Conclusion:
Comprehensive policy reform is necessary to balance environmental concerns with patient access and costs in inhaler therapies.